尿表皮生长因子与狼疮肾炎肾脏预后的关联
该研究通过蛋白质组学发现尿表皮生长因子(EGF)在活动性狼疮肾炎(LN)患者中显著降低,并在两个大型多民族LN队列中验证。尿EGF水平与肾脏活检慢性指数呈负相关,且发作时低尿EGF及随时间下降与长期不良肾脏结局相关。
要点
- 活动性LN患者尿EGF水平显著低于健康对照、活动性非肾性SLE及非活动性SLE患者。
- 尿EGF水平与肾脏活检病理慢性指数呈负相关(Spearman's r=-0.67,P<0.001)。
- 发作时低尿EGF及12个月内下降与血清肌酐倍增和终末期肾病进展相关。
核心结论
- 尿EGF水平与LN患者肾脏组织学损伤相关,发作时低尿EGF及随时间下降与不良长期肾脏结局相关。
研究设计与样本
- 发现队列用蛋白质组学鉴定尿EGF,并在2个大型多民族LN队列中验证表达。
- 在120例有长期随访数据的LN患者中评估发作时尿EGF与肾脏结局的关联。
- 在2个纵向LN队列的系列尿样本中确定尿EGF随时间的变化。
主要发现
- 发现分析显示活动性LN患者尿EGF中位肽计数8.4(IQR 2.8-12.3),健康对照中位48.0(IQR 45.3-64.6)。
- 活动性LN患者尿EGF显著低于活动性非肾性SLE、非活动性SLE和健康肾供者(各P<0.05)。
- 尿EGF与肾脏活检慢性指数呈负相关(Spearman's r=-0.67,P<0.001)。
- 多变量生存分析显示尿EGF与血清肌酐倍增时间相关(HR 0.88,95%CI 0.77-0.99,P=0.045)。
- 进展至血清肌酐倍增和终末期肾病的患者发作时尿EGF更低,且发作后12个月内尿EGF下降;尿EGF切点<5.3 ng/mg识别出所有进展至终末期肾病的患者。
关键数值与推荐
- 尿EGF切点<5.3 ng/mg可识别所有进展至终末期肾病的患者。
临床怎么用
- 尿EGF可作为LN肾脏慢性损伤的无创生物标志物,辅助评估发作时及随访中的肾脏预后风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the role of urinary epidermal growth factor (EGF) as a biomarker of chronic kidney damage in lupus nephritis (LN). METHODS: A proteomics approach was used to identify urinary EGF as a biomarker of interest in a discovery cohort of patients with LN. The expression of urinary EGF was characterized in 2 large multiethnic LN cohorts, and the association between urinary EGF levels at the time of flare and kidney outcomes was evaluated in a subset of 120 patients with long-term follow-up data. For longitudinal studies, the expression of urinary EGF over time was determined in 2 longitudinal cohorts of patients with LN from whom serial urine samples were collected. RESULTS: Discovery analysis showed the urinary EGF levels as being low in patients with active LN (median peptide count 8.4, interquartile range [IQR] 2.8-12.3 in patients with active LN versus median 48.0, IQR 45.3-64.6 in healthy controls). The peptide sequence was consistent with that of proEGF, and this was confirmed by immunoblotting. The discovery findings were verified by enzyme-linked immunosorbent assay. Patients with active LN had a significantly lower level of urinary EGF compared to that in patients with active nonrenal systemic lupus erythematosus (SLE), patients with inactive SLE, and healthy kidney donors (each P < 0.05). The urinary EGF level was inversely correlated with the chronicity index of histologic features assessed in kidney biopsy tissue (Spearman's r = -0.67, P < 0.001). Multivariate survival analysis showed that the urinary EGF level was associated with time to doubling of the serum creatinine level (DSCr), a marker of future end-stage kidney disease (ESKD) (hazard ratio 0.88, 95% confidence interval 0.77-0.99, P = 0.045). Patients whose LN symptoms progressed to DSCr and those who experienced progression to ESKD had a lower urinary EGF level at the time of flare, and urinary EGF levels decreased over the 12 months following flare. All patients who experienced progression to ESKD were identified based on a urinary EGF cutoff level of <5.3 ng/mg. CONCLUSION: Urinary EGF levels are correlated with histologic kidney damage in patients with LN. Low urinary EGF levels at the time of flare and decreasing urinary EGF levels over time are associated with adverse long-term kidney outcomes.
引用
- Mejia-Vilet JM, Shapiro JP, Zhang XL, et al. Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus Nephritis. Arthritis Rheumatol. 2021. PMID: 32892508. doi:10.1002/art.41507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。